强敏, 施晓疌, 张楚悦, 马培翔, 杨光 . 组合抗体库技术的研究进展[J]. 自然杂志, 2021 , 43(5) : 374 -382 . DOI: 10.3969/j.issn.0253-9608.2021.05.008

[1] LERNER R A. Manufacturing immunity to disease in a test tube: the magic bullet realized [J]. Angew Chem Int Ed, 2006, 45(48): 8106- 8125. 

[2] ORLANDI R, GUSSOW D H, JONES P T, et al. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction [J]. Proc Natl Acad Sci USA, 1989, 86(10): 3833-3837. 

[3] PERSSON M A. Twenty years of combinatorial antibody libraries, but how well do they mimic the immunoglobulin repertoire? [J]. Proc Natl Acad Sci USA, 2009, 106(48): 20137-20138. 

[4] LERNER R A. Combinatorial antibody libraries: new advances, new immunological insights [J]. Nat Rev Immunol, 2016, 16(8): 498-508. 

[5] LIN C W, LERNER R A. Antibody libraries as tools to discover functional antibodies and receptor pleiotropism [J]. Int J Mol Sci, 2021, 22(8): 4123. 

[6] XIE J, ZHANG H, YEA K, et al. Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells [J]. Proc Natl Acad Sci USA, 2013, 110(20): 8099-8104. 

[7] ZHANG H, XIE J, LERNER R A. A proximity based general method for identification of ligand and receptor interactions in living cells [J]. Biochem Biophys Res Commun, 2014, 454(1): 251-255. 

[8] MA P, REN P, ZHANG C, et al. Avidity-based selection of tissuespecific CAR-T cells from a combinatorial cellular library of CARs [J]. Adv Sci, 2021, 8(6): 2003091. 

[9] YANG Z, WAN Y, TAO P, et al. A cell-cell interaction format for selection of high-affinity antibodies to membrane proteins [J]. Proc Natl Acad Sci USA, 2019, 116(30): 14971-14978. 

[10] ZHENG T, XIE J, YANG Z, et al. Antibody selection using clonal cocultivation of Escherichia coli and eukaryotic cells in miniecosystems [J]. Proc Natl Acad Sci USA, 2018, 115(27): E6145-E6151. 

[11] SMITH G P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface [J]. Science, 1985, 228(4705): 1315-1317. 

[12] HUSE W D, SASTRY L, IVERSON S A, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda [J]. Science, 1989, 246(4935): 1275-1281. 

[13] MCCAFFERTY J, GRIFFITHS A D, WINTER G, et al. Phage antibodies: filamentous phage displaying antibody variable domains [J]. Nature, 1990, 348(6301): 552-554. 

[14] ALFALEH M A, ALSAAB H O, MAHMOUD A B, et al. Phage display derived monoclonal antibodies: from bench to bedside [J]. Front Immunol, 2020, 11: 1986. 

[15] JESPERS L S, ROBERTS A, MAHLER S M, et al. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen [J]. Nature Biotechnology (NY), 1994, 12(9): 899-903. 

[16] EDWARDS B M, BARASH S C, MAIN S H, et al. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS [J]. J Mol Biol, 2003, 334(1): 103-118. 

[17] MAZUMDAR S. Raxibacumab [J]. MAbs, 2009, 1(6): 531-538. 

[18] LU D, JIMENEZ X, ZHANG H, et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy [J]. Int J Cancer, 2002, 97(3): 393-399. 

[19] DE HAARD H J, VAN NEER N, REURS A, et al. A large non immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies [J]. J Biol Chem, 1999, 274(26): 18218-18230. 

[20] LI S, KUSSIE P, FERGUSON K M. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8 [J]. Structure, 2008, 16(2): 216-227. 

[21] MCDERMOTT D F, SOSMAN J A, SZNOL M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study [J]. J Clin Oncol, 2016, 34(8): 833-842. 

[22] HERBST R S, SORIA J C, KOWANETZ M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J]. Nature, 2014, 515(7528): 563-567. 

[23] BOYERINAS B, JOCHEMS C, FANTINI M, et al. Antibodydependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells [J]. Cancer Immunol Res, 2015, 3(10): 1148-1157. 

[24] MARKHAM A. Guselkumab: first global approval [J]. Drugs, 2017, 77(13): 1487-1492. 

[25] KENNISTON J A, FAUCETTE R R, MARTIK D, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody [J]. J Biol Chem, 2014, 289(34): 23596-23608. 

[26] SALVATORE G, BEERS R, MARGULIES I, et al. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display [J]. Clin Cancer Res, 2002, 8(4): 995-1002. 

[27] ALDERSON R F, KREITMAN R J, CHEN T, et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies [J]. Clin Cancer Res, 2009, 15(3): 832-839. 

[28] CATTANEO A, BIOCCA S. The selection of intracellular antibodies [J]. Trends Biotechnol, 1999, 17(3): 115-121. 

[29] WULFF H, CHRISTOPHERSEN P, COLUSSI P, et al. Antibodies and venom peptides: new modalities for ion channels [J]. Nat Rev Drug Discov, 2019, 18(5): 339-357. 

[30] ALVAREZ DE LA ROSA D, CANESSA C M, FYFE G K, et al. Structure and regulation of amiloride-sensitive sodium channels [J]. Annu Rev Physiol, 2000, 62: 573-594. 

[31] QIANG M, DONG X, ZHA Z, et al. Selection of an ASIC1ablocking combinatorial antibody that protects cells from ischemic death [J]. Proc Natl Acad Sci USA, 2018, 115(32): E7469-E7477. 

[32] GOODENOUGH D A, REVEL J P. A fine structural analysis of intercellular junctions in the mouse liver [J]. J Cell Biol, 1970, 45(2): 272-290. 

[33] SRINIVAS M, VERSELIS V K, WHITE T W. Human diseases associated with connexin mutations [J]. Biochim Biophys Acta Biomembr, 2018, 1860(1): 192-201. 

[34] GARCIA I E, MARIPILLAN J, JARA O, et al. Keratitis-ichthyosisdeafness syndrome-associated Cx26 mutants produce nonfunctional gap junctions but hyperactive hemichannels when co-expressed with wild type Cx43 [J]. J Invest Dermatol, 2015, 135(5): 1338-1347. 

[35] XU L, CARRER A, ZONTA F, et al. Design and characterization of a human monoclonal antibody that modulates mutant connexin 26 hemichannels implicated in deafness and skin disorders [J]. Front Mol Neurosci, 2017, 10: 298. 

[36] KUANG Y, ZORZI V, BURATTO D, et al. A potent antagonist antibody targeting connexin hemichannels alleviates clouston syndrome symptoms in mutant mice [J]. EBioMedicine, 2020, 57: 102825. 

[37] RATHORE A S, SARKER A, GUPTA R D. Recent developments toward antibody engineering and affinity maturation [J]. Protein Pept Lett, 2018, 25(10): 886-896. 

[38] YLERA F, HARTH S, WALDHERR D, et al. Off-rate screening for selection of high-affinity anti-drug antibodies [J]. Anal Biochem, 2013, 441(2): 208-213. 

[39] FELDHAUS M J, SIEGEL R W. Yeast display of antibody fragments: a discovery and characterization platform [J]. J Immunol Methods, 2004, 290(1/2): 69-80. 

[40] CHAO G, LAU W L, HACKEL B J, et al. Isolating and engineering human antibodies using yeast surface display [J]. Nat Protoc, 2006, 1(2): 755-768.

[41] YANG Z, DU M, WANG W, et al. Affinity maturation of an TpoR targeting antibody in full-length IgG form for enhanced agonist activity [J]. Protein Eng Des Sel, 2018, 31(7/8): 233-241. 

[42] SHI X, WAN Y, WANG N, et al. Selection of a picomolar antibody that targets CXCR2-mediated neutrophil activation and alleviates EAE symptoms [J]. Nature Communications, 2021, 12(1): 2547. 

[43] TAO P, KUANG Y, LI Y, et al. Selection of a full agonist combinatorial antibody that rescues leptin deficiency in vivo [J]. Adv Sci, 2020, 7(16): 2000818. 

[44] HUTCHINGS C J, COLUSSI P, CLARK T G. Ion channels as therapeutic antibody targets [J]. MAbs, 2019, 11(2): 265-296. [45] HUTCHINGS C J, KOGLIN M, MARSHALL F H. Therapeutic antibodies directed at G protein-coupled receptors [J]. MAbs, 2010, 2(6): 594-606. 

[46] WANG X X, SHUSTA E V. The use of scFv-displaying yeast in mammalian cell surface selections [J]. J Immunol Methods, 2005, 304(1/2): 30-42. 

[47] TILLOTSON B J, CHO Y K, SHUSTA E V. Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display [J]. Methods, 2013, 60(1): 27-37. 

[48] LERNER R A, GROVER R K, ZHANG H, et al. Antibodies from combinatorial libraries use functional receptor pleiotropism to regulate cell fates [J]. Q Rev Biophys, 2015, 48(4): 389-394. 

[49] YEA K, XIE J, ZHANG H, et al. Selection of multiple agonist antibodies from intracellular combinatorial libraries reveals that cellular receptors are functionally pleiotropic [J]. Curr Opin Chem Biol, 2015, 26: 1-7. 

[50] YEA K, ZHANG H, XIE J, et al. Agonist antibody that induces human malignant cells to kill one another [J]. Proc Natl Acad Sci USA, 2015, 112(45): E6158-E6165. 

[51] ZHANG H, WILSON I A, LERNER R A. Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries [J]. Proc Natl Acad Sci USA, 2012, 109(39): 15728-15733. 

[52] YEA K, ZHANG H, XIE J, et al. Converting stem cells to dendritic cells by agonist antibodies from unbiased morphogenic selections [J]. Proc Natl Acad Sci USA, 2013, 110(37): 14966-14971. 

[53] XIE J, YEA K, ZHANG H, et al. Prevention of cell death by antibodies selected from intracellular combinatorial libraries [J]. Chemistry Biology, 2014, 21(2): 274-283. 

[54] BLANCHARD J W, XIE J, EL-MECHARRAFIE N, et al. Replacing reprogramming factors with antibodies selected from combinatorial antibody libraries [J]. Nat Biotechnol, 2017, 35(10): 960-968. 

[55] WANG Z, WU Z, LIU Y, et al. New development in CAR-T cell therapy [J]. J Hematol Oncol, 2017, 10(1): 53. [56] MIKKILINENI L, KOCHENDERFER J N. CAR T cell therapies for patients with multiple myeloma [J]. Nat Rev Clin Oncol, 2021, 18(2): 71-84. 

[57] ALI S A, SHI V, MARIC I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma [J]. Blood, 2016, 128(13): 1688-1700. 

[58] BRUDNO J N, KOCHENDERFER J N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management [J]. Blood Rev, 2019, 34: 45-55. 

[59] DAI H, WANG Y, LU X, et al. Chimeric antigen receptors modified T-cells for cancer therapy [J]. J Natl Cancer Inst, 2016, 108(7): 439. 

[60] DRENT E, THEMELI M, POELS R, et al. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization [J]. Mol Ther, 2017, 25(8): 1946- 1958. 

[61] LAMERS C H, LANGEVELD S C, GROOT-VAN RUIJVEN C M, et al. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo [J]. Cancer Immunol Immunother, 2007, 56(12): 1875-1883.